Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Jounce Therapeutics Inc (JNCE)

Jounce Therapeutics Inc (JNCE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 270,152
  • Shares Outstanding, K 33,229
  • Annual Sales, $ 65,200 K
  • Annual Income, $ -27,380 K
  • 60-Month Beta 3.73
  • Price/Sales 3.97
  • Price/Cash Flow N/A
  • Price/Book 1.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.41
  • Number of Estimates 5
  • High Estimate 0.30
  • Low Estimate -0.75
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -583.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.17 +95.32%
on 11/11/19
9.80 -16.89%
on 12/04/19
+4.09 (+100.62%)
since 11/08/19
3-Month
2.79 +191.94%
on 10/04/19
9.80 -16.89%
on 12/04/19
+4.32 (+112.66%)
since 09/10/19
52-Week
2.66 +206.20%
on 12/26/18
9.80 -16.89%
on 12/04/19
+4.27 (+109.92%)
since 12/10/18

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Jounce Therapeutics, Forterra, Hibbett Sports, Foundation Building Materials and Orion Energy Systems

The Zacks Analyst Blog Highlights: Jounce Therapeutics, Forterra, Hibbett Sports, Foundation Building Materials and Orion Energy Systems

OESX : 3.62 (+2.26%)
FRTA : 9.78 (-1.41%)
HIBB : 27.52 (+1.51%)
FBM : 20.11 (+0.35%)
JNCE : 8.30 (+2.09%)
Is the Options Market Predicting a Spike in Jounce Therapeutics (JNCE) Stock?

Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately.

JNCE : 8.30 (+2.09%)
Small Business Optimism Rises Amid Trade Jitters: 5 Top Picks

A section of the U.S. business community - the small business segment - seems optimistic about the future despite trade-related hiccups.

OESX : 3.62 (+2.26%)
FRTA : 9.78 (-1.41%)
HIBB : 27.52 (+1.51%)
FBM : 20.11 (+0.35%)
JNCE : 8.30 (+2.09%)
Jounce Therapeutics, Inc. (JNCE) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor Jounce Therapeutics, Inc. (JNCE).

JNCE : 8.30 (+2.09%)
Top Ranked Momentum Stocks to Buy for December 2nd

Top Ranked Momentum Stocks to Buy for December 2nd

TNK : 20.56 (-0.24%)
TGT : 125.89 (-0.44%)
JNCE : 8.30 (+2.09%)
GH : 72.44 (+0.40%)
The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical

The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical

BDSI : 6.38 (-0.16%)
IRWD : 12.35 (+0.16%)
SEM : 22.92 (+0.09%)
JNCE : 8.30 (+2.09%)
OSMT : 6.85 (+1.78%)
Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD

Healthcare bounced back with an outperformance starting the fourth quarter.

CNCR : 23.21 (+0.04%)
SBIO : 42.35 (+1.15%)
IHF : 193.30 (-0.32%)
BBC : 35.42 (+0.68%)
IRWD : 12.35 (+0.16%)
SEM : 22.92 (+0.09%)
OSMT : 6.85 (+1.78%)
JNCE : 8.30 (+2.09%)
GNOM : 15.85 (-0.15%)
Value ETFs & Stocks Offering Real Value: 5 Top Picks

A favorable operating backdrop and cheap valuation are leading value stocks higher. Play the trend with these cheap value stocks and ETFs.

PHM : 40.09 (-0.17%)
PFSI : 33.48 (-0.65%)
FTXO : 27.70 (-0.14%)
IVAL : 29.26 (-0.10%)
INVA : 13.40 (+0.75%)
NSIT : 65.40 (+0.05%)
JNCE : 8.30 (+2.09%)
SPVU : 37.77 (-0.26%)
IVLU : 24.22 (+0.12%)
ESGN : 25.96 (-0.73%)
5 High-Beta ETFs & Stocks for a Record Market

While every corner of the market is enjoying the current ascent, high-beta ETFs and stocks seem a perfect bet at present.

SQ : 66.21 (-1.27%)
ENTR : 18.10 (-0.20%)
RZV : 68.48 (-0.49%)
SPHB : 44.30 (+0.29%)
RFV : 69.04 (+0.05%)
CVEO : 0.84 (+1.20%)
HEES : 32.02 (-0.25%)
HNGR : 26.78 (+0.26%)
JNCE : 8.30 (+2.09%)
VFVA : 76.16 (+0.02%)
Jounce Therapeutics, Inc. (JNCE) Q3 Earnings and Revenues Surpass Estimates

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 28.89% and 19.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the...

JNCE : 8.30 (+2.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade JNCE with:

Business Summary

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator,...

See More

Key Turning Points

2nd Resistance Point 8.82
1st Resistance Point 8.47
Last Price 8.21
1st Support Level 7.69
2nd Support Level 7.26

See More

52-Week High 9.80
Last Price 8.21
Fibonacci 61.8% 7.07
Fibonacci 50% 6.23
Fibonacci 38.2% 5.39
52-Week Low 2.66

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar